sciclone pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals

SCLN 11.15

0.0%

Oct 20 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: energyplay who wrote (947)	8/30/2001 10:09:11 PM
From: JEB	Read Replies (1) of 1137

Reasonable valuation is a subjective term for a biotech (and let's be real, we are a biotech no matter how the street treats us). Case in point: ENZN last quarter had a P/E over 400, this quarter it has a P/E of 248. The US market is a big market, as well as Japan and Europe. The big three. Any one of these can make you profitable, quickly. SCLN needs to crack any one of these markets for more market growth and greater sales stability (exchange rate). It's impressive where we have come from but we still have a long way to go. ;-) JEB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next